Back to Search Start Over

Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300.

Authors :
Marvaso, Giulia
Vischioni, Barbara
Pepa, Matteo
Zaffaroni, Mattia
Volpe, Stefania
Patti, Filippo
Bellerba, Federica
Gandini, Sara
Comi, Stefania
Corrao, Giulia
Zerini, Dario
Augugliaro, Matteo
Fodor, Cristiana
Russo, Stefania
Molinelli, Silvia
Ciocca, Mario
Ricotti, Rosalinda
Valvo, Francesca
Giandini, Tommaso
Avuzzi, Barbara
Source :
Frontiers in Oncology; 11/17/2021, Vol. 11, p1-9, 9p
Publication Year :
2021

Abstract

Purpose: This study represents a descriptive analysis of preliminary results of a Phase II trial on a novel mixed beam radiotherapy (RT) approach, consisting of carbon ions RT (CIRT) followed by intensity-modulated photon RT, in combination with hormonal therapy, for high-risk prostate cancer (HR PCa) with a special focus on acute toxicity. Methods: Primary endpoint was the evaluation of safety in terms of acute toxicity. Secondary endpoints were early and long-term tolerability of treatment, quality of life (QoL), and efficacy. Data on acute and late toxicities were collected according to RTOG/EORTC. QoL of enrolled patients was assessed by IPSS, EORTC QLQ-C30, EORTC QLQ-PR25, and sexual activity by IIEF-5. Results: Twenty-six patients were enrolled in the study, but only 15 completed so far the RT course and were included. Immediately after CIRT, no patients experienced GI/GU toxicity. At 1 and 3 months from the whole course RT completion, no GI/GU toxicities greater than grade 2 were observed. QoL scores were overall satisfactory. Conclusions: The feasibility of the proposed mixed treatment schedule was assessed, and an excellent acute toxicity profile was recorded. Such findings instil confidence in the continuation of this mixed approach, with evaluation of long-term tolerability and efficacy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
2234943X
Volume :
11
Database :
Complementary Index
Journal :
Frontiers in Oncology
Publication Type :
Academic Journal
Accession number :
153624803
Full Text :
https://doi.org/10.3389/fonc.2021.778729